B7-H3 is a tumor-associated antigen that plays a critical role in potential tumortargeted therapy. In this study, we aimed to assess the radiobiological effect of 
I-labeled B7-H3 monoclonal antibody ( 131 I-4H7) in nude mice with human renal cell carcinoma (RCC) and evaluate the effect of
I-4H7 on RCC treatment. The radiobiological activity and tumor uptake of 131 I-4H7, and its effect on tumor growth were measured. 131 I-4H7 was absorbed by the tumor and reached its maximal uptake rate (3.32% injected dose [ID]/g) at 24 h, at which point the drug concentration in the tumor was 7.36-, 2.06-, 1.80-, and 2.78-fold higher than that in muscle, kidneys, liver, and heart, respectively. Measurements and positron emission tomographycomputed tomography imaging showed that tumor development was significantly inhibited by 131 I-4H7. HE staining revealed that 131 I-4H7 significantly injures tumor cells. Our results suggest that 131 I-4H7 is markedly absorbed by the tumor and did suppress the development of RCC xenografted tumors in nude mice, which might provide a new candidate for antibody-mediated targeted radiotherapy in human RCC.
IntroductIon
Renal cell carcinoma (RCC) is the most common malignant tumor in the adult kidney, accounting for 2.0-3.0% of all human malignancies [1] , and its occurrence has increased in recent years [2] [3] [4] .The incidence of RCC worldwide is approximately 209, 000 new cases per year and 102, 000 deaths per year [5] . In the United States, it is estimated that there will be ~61, 560 new cases and 14, 080 deaths of kidney and renal pelvis cancer in 2015 [6] . Recent studies have clearly shown that the clear-cell tumor subtype is the most frequent, accounting for >80% of all RCCs [7, 8] . Radical surgery is the most effective treatment option for early stage RCC. Unfortunately, 15-25% of patients present with a metastatic disease at the time of diagnosis and 30% of the localized disease will relapse into a metastatic setting during the years following surgery. The lack of any demonstrable efficacy from chemotherapy and radiation therapy in advanced RCC has led to a 5.0-year survival rate ranging from 5.0 to 10.0% [9, 10] .
B7-H3, a member of the B7 immunoregulatory family, was identified in 2001 by database searches of a human dendritic cell-derived cDNA library [11] . B7-H3 is broadly expressed at the transcriptional level and is found in a wide spectrum of both human solid tumors and normal tissues, while at the protein level, B7-H3 can be expressed in dendritic cells and in the liver, lungs, and prostate as well as in most tumor cell lines. B7-H3 was identified as the most differentially expressed cell-surface tumorspecific endothelial marker [12] . Studies have shown that tumor B7-H3 expression is correlated with poor patient survival in both clear cell RCC (ccRCC) and urothelial cell carcinoma [13, 14] . Qin et al. [15] . found that the expression of B7-H3 was not only detected in ccRCC specimens, but was also confirmed in RCC vasculature, and that the vascular B7-H3 expression was associated with multiple adverse clinical and pathologic features. In addition, B7-H3 expression in tumor vasculature was also correlated with poor survival, suggesting that this ligand might play an important role in tumor cell migration [15, 16] ; therefore, B7-H3 might be a useful target for tumorspecific antiangiogenic therapies [17] .
Targeted therapy, which has radically altered the treatment of late-stage RCC in recent years, relies on the following two main groups of agents: vascular endothelial growth factor (VEGF)-targeting drugs and mammalian target of rapamycin (mTOR) inhibitors. Nevertheless, despite recent success, complete response to antiangiogenic therapies is rare. One study showed that 80.95% of patients receiving 131 I-B7-H3 monoclonal antibody (8H9) salvage therapy had prolonged survival times after a central nervous system (CNS) neuroblastoma relapse [18] . These findings led us to hypothesize that the specific expression of B7-H3 in the RCC vasculature system could make it a prominent carrier for B7-H3 image-and receptor-mediated targeted radiotherapy. Utilizing 131 I as a radiotherapeutic nuclide and monoclonal antibody B7-H3 (4H7) as a carrier, the feasibility and efficacy of B7-H3-mediated 131 I-4H7 targeted radiotherapy was analyzed in a human RCC xenograft model.
results clinical tissue samples and immunohistochemical staining
Immunohistochemical (IHC) staining analysis showed significantly more B7-H3 staining in the tumor cells, tumor vasculatures, and stroma of the ccRCC samples than in normal renal specimens ( Figure 1A-1D) , which was consistent with the previously reported study results [16] . I-mIgG was examined in these mice. For 131 I-4H7, the tumor uptake was determined to be 2.72 ± 0.49, 2.32 ± 0.77, 2.25 ± 0.69, 3.32 ± 0.46, 1.34 ± 0.20, and 1.13 ± 0.28% ID/g at 2.0, 4.0, 8.0, 24, 48, and 72 h, respectively. Its uptake rate peaked at 24 h, at which point the drug concentration in the tumor was 7.36-, 2.06-, 1.80-, 1.67-, and 2.78-fold higher than that in the muscle, kidneys, liver, lung and heart, respectively ( Figure 3A ). Its uptake rate also peaked at 24 h, at which point the drug concentration in the tumor was 5.02-, 1.58-, 1.39-, 1.29-, and 2.09-fold higher than that in muscle, kidneys, liver, lung and heart, respectively ( Figure 3B ).
131 I-4H7 exhibited 7.39 ± 1.11% ID/g liver uptake compared with 6.36 ± 1.11% ID/g in 131 I-mIgG at 2.0 h post-injection ( Figure 3A -3B).
131
I-4H7 showed 5.67 ± 0.68% ID/g of kidney uptake, which is higher than that of 131 I-mIgG (4.64 ± 0.68% ID/g) at 2.0 h pi ( Figure 3A and 3B). It might be the reason that 4H7 metabolized mainly through the liver and kidneys. The nonspecific uptake in the muscle was at a very low level for both tracers.
131 I-4H7 exhibited greater tumor uptake at the early time point and better tumor retention, indicating a longer circulation time. In addition, 131 I-4H7 showed greater tumor uptake compared to that of 131 I-mIgG, and the 131 I-4H7 tumor/kidney ratio of was significantly higher than that of 131 I-mIgG ( Figure  3C ). Similar tumor/muscle, tumor/liver, and tumor/heart ratios were observed for both 131 I-4H7 and 131 I-mIgG ( Figure 3C ).
Positron emission tomography /computed tomography (Pet-ct) imaging studies
The effect of 131 I-4H7, 
Hematoxylin-eosin staining
The saline-and 131 I-treated groups were characterized by well-developed proliferations of ccRCC cells, with a compact arrangement and diffusely distributed invading cancer nests; the nuclei were of various sizes and there was no apparent necrosis in the cancer tissue ( Figure  6A-6B) . The 131 I-4H7 and 131 I-mIgG treated groups were characterized by a large field of ccRCC cell necrosis, with dying tumor cells undergoing vacuolar degeneration of the cytoplasm (Figure 6C-6D ). There were more regions of necrosis in the 131 I-4H7 group than in the 131 I-mIgG group ( Figure 6C-6D) .
dIscussIon
RCC is the most common malignant tumor in the adult kidney and its incidence increases annually. RCC is a heterogeneous group of cancers with disparate genetic and molecular alterations underlying the various recognized histological subtypes. Considering that RCC possesses multiple drug-resistant genes and is not sensitive to traditional chemotherapy and radiotherapy, prognosis of advanced RCC remains poor, with <10% of patients still living 5.0 years after diagnosis of the metastatic disease [9, 10] . Monoclonal antibodies are often directed toward cellsurface molecules and can be radiolabeled for the imaging or treatment of cancer and other ailments [19] [20] [21] .Targeted agents against VEGF, VEGFR, or mTOR continue to play a crucial role in the management of metastatic ccRCC [22] .
B7-H3 was discovered firstly by Chen in 2001 [11] ; however, the physiological and pathological role of B7-H3 is far less well known and both stimulatory and inhibitory effects have been described for this ligand. Recent studies have indicated that B7-H3 overexpression was found in several tumors, such as prostate cancer, non-small-cell lung carcinoma, and RCC. In addition, B7-H3 is expressed in both RCC cells and tumor vessels and was marked as expressed in RCC vasculatures in some studies as high as 98% [15] , which indicates that B7-H3 could act as a potent new cancer vessel-specific carrier to selectively deliver antiangiogenic or vascular-disrupting agents to diseased tissues, minimize any potential side effects, and could help predict the clinical outcome of using different targeted agents in the treatment of RCC.
In the present study, the level of B7-H3 expression was higher in the tumor cells, tumor vasculatures, and stroma of the ccRCC samples than in normal renal specimens, which was consistent with previous studies, providing a theoretical basis for 131 I-labeled targeted radiotherapy for RCC using B7-H3 monoclonal antibody (4H7) as a carrier. The biodistribution studies indicated that the radiochemical purities of both 131 I-4H7 and 131 I-mIgG were >95%, and the stability of both traces in PBS was >95% after incubating for 72 h. Moreover, the tissue distribution experiments showed that 131 I-4H7 was markedly absorbed by tumor tissue in tumor-bearing nude mice, reaching a maximal uptake rate (3.32% ID/g) at 24 h after intravenous injection. The retention of 131 I-4H7 was such that at 72 h, the uptake rate remained at 1.13% ID/g, indicating that 4H7 kept its activity after being radioiodinated by 131 I, which showed that it could be absorbed by RCC tissues and suggested that it might make a useful clinical candidate for a RCC-targeting treatment option. All normal tissue concentrations decreased over time but this did not occur to a great extent in the tumors. It might be possible that the uptake rate of 131 I-4H7 does not distinctly reflect the accumulation of 4H7 in vivo because of the many enzymes that can accelerate the catabolism and deiodination of 131 I-4H7 in normal tissue, but in tumors, this does not appear to be the case, and the accumulation of 131 I-4H7 is gradually increased by the action of B7-H3. This is advantageous to the treatment of the tumors with radiotherapy.
Our therapeutic experiments showed that 131 I-4H7 and 131 I-mIgG treatment through intravenous injection could inhibit tumor growth and alter the ultrastructure and histopathology of RCC cells, resulting in irreversible injury and wide necrosis, and that the therapeutic effect was more pronounced in the 131 I-4H7 group than in the 131 I-mIgG group. The results indicated that the targeted effect of 131 I-4H7 is better than that in 131 I-mIgG. Moderate energy β-particles from 131 I-4H7 targeted to tumor vasculatures in vivo were sufficiently damaging to tumor vasculatures, which could lead to damaging tumor angiogenesis, causing the hypoxic ischemia necrosis of tumor cells. Several researches have indicated that cancer cell-specific B7-H3 expression in ccRCC is ~20% [13, 15] , although lower than that in tumor vasculatures, and that the direct cytotoxic effect on ccRCC cells of 131 I-4H7 cannot be completely ruled out.
In the therapeutic experiments, 131 I-4H7 treatment could inhibit tumor growth and cause irreversible injury to RCC cells and tumor vasculatures, but we did not find tumor regression in the 131 I-4H7 group, which could be related to the dose of 131 I-4H7, which might not have been sufficient (Supplementary Figure 1) . Further studies are needed to clarify the effect of different doses of 131 I-4H7 on tumor growth. Meanwhile, there was no metastasis in tumor-bearing nude mice treated with 131 I-4H7 and the other three agents, which indicated that the dose of 131 I-4H7 was correct and safe.
In conclusion, our results indicate that the radiobiological effect of 131 I-4H7 is stable and 131 I-4H7 did suppress the development of human RCC xenografted tumors in nude mice at day 28, which might provide a new candidate for B7-H3 receptor-mediated targeted radiotherapy in human ccRCC.
MAterIAls And MetHods clinical sample collection
Twenty-six patients with ccRCC who underwent surgery for radical nephrectomy were included in the study. Paired samples of ccRCCs and adjacent normal tissues were immediately placed on ice, partitioned, and fixed in 10% formalin. Patients were excluded from the study if they had received chemotherapy or radiation therapy before the surgical procedure or had undergone previous renal surgery. ccRCC specimens were confirmed by postoperative pathological diagnosis. Written informed consent was obtained from each patient and this study was approved by the Ethics Committee of The First Affiliated Hospital of Soochow University and Huai'an First People's Hospital of Nanjing Medical University, China.
cell culture and animal model
The human ccRCC-derived cell line 786-0 was purchased from the Institute of Cell Research, Chinese Academy of Sciences, Shanghai, China. Cells were cultured in RPMI 1640 medium (Gibco Invitrogen, New York, USA) supplemented with 10% fetal bovine serum (Gibco Invitrogen, New York, USA) at 37˚C in an atmosphere of 5.0% CO 2 . One hundred twenty male BALB/c nude mice (5-6 weeks old and weighing 20-24 g) were obtained from the West China Experimental Animal Center of Sichuan University. These nude mice were bred under aseptic-specified pathogen-free (SPF) conditions and kept at a constant humidity and temperature (25-28˚C). Animal experiments were performed according to protocols approved by the Animal Care and Use Committee and were in compliance with the Guidelines on Animal Welfare of the China National Committee for Animal Experiments. Cells of 786-0 (2.0 x 10 7 ) in 0.2 mL normal sodium were injected subcutaneously into the right axilla region of the mice. When the tumors reached www.impactjournals.com/oncotarget 8.0 mm in diameter (1.0-2.0 weeks after inoculation), the tumor-bearing mice were used for biodistribution and therapeutic studies.
b7-H3 monoclonal antibody
131 I labeling B7-H3 monoclonal antibody (4H7) was constructed and prepared as previously described [23] . Na 131 I (37 TBq/L) was obtained from the Jiangsu Institute of Nuclear Medicine (China). To prepare the mixture, 100 μL 4H7 were dissolved in 150 μL phosphate buffered saline (PBS, pH 7.4) and mixed with 150 μL Na 131 I (approximately 185 MBq). The solution was mixed with 10 μL chloramine-T and vortexed for 60 s, after which the reaction was immediately halted using 100 μL partial glue solution. The product was purified by column (Bio-Gel P-2 resin, 300 × 10 mm) with PBS. The peak 131 I-4H7 solution was collected and refiltered through a 0.22-μm membrane. Using Xinhua I filter paper developed with 1:1 acetone and saline, a chromatographic assay of radiochemical purity was performed. Using the same procedure described above, 10 μL murine IgG (mIgG, isotype-matched control; Sigma-Aldrich Corp., St. Louis, MO, USA) were also labeled with 131 I as the negative control. The stability of 131 I-4H7 and 131 I-mIgG in PBS was studied at different time points and the percentage of parent tracer was determined by radio-thin layer chromatography.
biodistribution studies
The tumor-bearing nude mice were randomly divided into two groups of 36 mice each and 3.7 MBq (0.1 mCi) 131 I-4H7 and 131 I-mIgG, respectively, were injected into the tail vein of each. The mice were then sacrificed at 2.0, 4.0, 8.0, 24, 48, and 72 h after injection. The heart, lungs, kidneys, liver, muscle, and tumor were removed, weighed, and assayed for the 131 I-4H7 and 131 I-mIgG uptake rate. The uptake rate was determined by the percentage of radioactivity contained within each gram of tissue compared to the total radioactivity injected into the body. The tumor/nontumor tissue radioactive count (T/ NT) was then calculated. I to block free 131 I uptake by the thyroid. During this time, these mice were fed under SPF conditions. According to body weight and tumor size, the animals were divided into four experimental groups of 12 mice each, which were respectively treated with 0.2 mL saline, 0.2 mL 131 I (7.4
therapeutic studies

Groups and treatments
MBq), 0.2 mL 131 I-4H7 (7.4 MBq), or 0.2 mL 131 I-mIgG (7.4 MBq) injected into the tail vein of each. There were no fatalities among the treated mice during the study. to draw the growth curve and observe tumor growth [20] . All mice were sacrificed at day 28 and the tumors were removed and weighed. We regarded saline group as the control group, while groups of 131 I-4H7, 131 I-mIgG, and 131 I were all treated groups. The following formula was used to calculate the rate of tumor suppression:
Pet-ct imaging studies
Rate of tumor inhibition (100%) = (1 -mean tumor weight of treated group/mean tumor weight of control group) × 100% [24] .
Hematoxylin-eosin staining and immunohistochemical analysis
Clinical specimens and tumor xenograft specimens were fixed in 10% formalin and embedded in paraffin. We cut the paraffin-embedded specimens into sections of 5.0 μm and stained with hematoxylin and eosin (HE) for general morphological observation. Immunohistochemical (IHC) staining was performed using a rabbit-specific horseradish peroxidase/diaminobenzidine detection IHC kit (Abcam, Cambridge, UK) according to the manufacturer's protocol. Tissue sections were stained with anti-B7H3 (Abcam, Cambridge, UK, 1:200 dilution) for 30 min at room temperature, followed by incubation with secondary rabbit-specific HRP-conjugated antibodies for B7-H3 staining. Samples were visualized using a Nikon Eclipse 80i upright microscope (Nikon, Tokyo, Japan).
statistical analyses
Quantitative data are expressed as the mean ± SD. Means were compared using a one-way analysis of variance and Student's t test. p values < 0.05 were considered statistically significant. www.impactjournals.com/oncotarget ethical standards All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee of Soochow University and Nanjing Medical University, China. All participants gave written informed consent before participating in the study.
All animal and tissue sample experiments were performed in accordance with the guidelines of the National Institutes of Health and Soochow University with procedures (ID: 2012074) approved by the Institutional Animal Care and Use Committee of the university.
